ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

intismeran autogene

Also written as “Intismeran autogene”, “mRNA-4157” and “Intismeran”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Non-Muscle Invasive Bladder Neoplasms · Carcinoma, Renal Cell · Carcinoma, Squamous Cell, led by 2 companies.

Drug pageIntismeran autogene: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 27, 202312 company-led studies, 11 open or runningCo-development: Moderna and Merck, Oct 2022Next primary completion: Apr 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only109 open or runningphase 3since Jun 27, 2023Jun 27, 2023Apr 23, 2027phase 2 · NCT06305767
Moderna22 open or runningphase 2since Mar 29, 2019Oct 13, 2017Nov 21, 2027phase 1 · NCT03313778
  • Named in Merck’s own pipeline as intismeran autogene (V940), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Moderna only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2017First study: phase 1 study in Solid TumorsFirst studyNCT03313778 · 161 enrolled · United States, Australia, Japan and more
  2. Mar 29, 2019Phase 2 study in MelanomaNCT03897881 · 267 enrolled · United States, Australia
  3. Oct 12, 2022Merck develops it with ModernaCo-developmentWorldwide, costs and profits shared equally · announced · Merck
  4. Aug 11, 2024Named intismeran autogeneINNProposed as its International Nonproprietary Name in WHO's List 131

Ahead

  1. Nov 21, 2027Primary completion: phase 1 study in Solid TumorsNCT03313778
  2. Nov 21, 2032Primary completion: phase 2 study in MelanomaNCT03897881

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting thirty-four tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells and encapsulated in lipid nanoparticles, with potential immunostimulatory and antineoplastic activities.…”NCIt, read by Claude

Studies

All 2 Moderna leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03897881Melanoma · United States, Australia2Active, not recruitingNov 21, 2032267
NCT03313778Solid Tumors · United States, Australia, Japan and more1Active, not recruitingNov 21, 2027161

How it is read

Names in the registry

  • “Intismeran autogene”, 8 entries
  • “mRNA-4157”, 2 entries
  • “Intismeran”, 1 entry
  • “Intismeran Autogene”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.